Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers

Autor: Dekhnich A.V., Zubareva N.A., Kozlov R.S., Popov D.A., Romanov A.V., Rudnov V.A.
Jazyk: ruština
Rok vydání: 2015
Předmět:
Zdroj: Клиническая микробиология и антимикробная химиотерапия, Vol 17, Iss 2, Pp 127-145 (2015)
Druh dokumentu: article
ISSN: 1684-4386
2686-9586
Popis: Telavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) microorganisms, including multiresistant strains. Another perspective area of telavancin use — bloodstream infections, such as bacteremia and endocarditis. Telavancin is in vitro active against broad range of Gram(+) aerobic and anaerobic bacteria, including strains resistant to other antimicrobials: MRSA, MRSE, VISA, daptomycin non-susceptible strains of S. aureus, penicillin-resistant S. pneumoniae, ampicillin-resistant enterococci and enterococci with VanB phenotype of resistance to vancomycin. Talavancin is rapidly bactericidal due to its dual mechanism of action; it is active against intracellular bacterial cells and biofilmforming cells. Article reviews data of current in vitro and in vivo studies of telavancin, as well as clinical trials results.
Databáze: Directory of Open Access Journals